We have previously shown that malignant plasma cells expressed the specific receptor for 1,25-dihydroxyvitamin D₃ and that this derivative could significantly inhibit the proliferation of such malignant cells. More recently, new vitamin D₃ derivatives have been generated with extraordinarily potent inhibitory effects on leukemic cell growth in vitro. These new data prompted us to (re)investigate the capacity of such new vitamin D₃ derivatives to inhibit myeloma cell growth in comparison with that of dexamethasone, a potent antitumoral agent in multiple myelomas. In the current study, we show that EB1089, a new vitamin D₃ derivative, (1) induces G1 growth arrest of human myeloma cells, which is only partially reversed by interleukin-6 (IL-6); (2) induces apoptosis in synergy with dexamethasone, IL-6, leukemia-inhibitory factor, and Oncostatin M, with an agonistic anti-gp130 monoclonal antibody being unable to prevent this apoptosis; (3) downregulates both the gp80 (i.e., the α chain of the IL-6 receptor [IL-6Ra]) expression on malignant plasma cells and the production of soluble IL-6Ra, and finally (4) inhibits the deleterious upregulation of gp80 expression induced by dexamethasone while limiting the dexamethasone-induced upregulation of gp130 expression. Considering that these in vitro effects of EB1089 have been observed at doses obtainable in vivo (without hypercalcemic effects), our present data strongly suggest that EB1089 could have a true interest in the treatment of multiple myeloma, especially in association with dexamethasone.

© 1996 by The American Society of Hematology.

MATERIALS AND METHODS

Reagents. Dexam was obtained from Merck Sharp USA (Paris, France). 1,25(OH)₂D₃ and the derivative EB1089 were obtained from Leo Pharmaceuticals (Ballerup, Denmark). Anti-gp80 MoAb (MT18) and anti-gp130 MoAb (AM64) were provided by Dr Taga (Institute for Molecular and Cellular Biology, Osaka University, Osaka, Japan). The agonistic anti-gp130 MoAb (BS12) was kindly provided by Dr J. Wijdenes (Dianclone Research, Besançon, France). Human recombinant IL-6 and Oncostatin M (OSM) were obtained from Sandoz (East Hanover, NJ) and Dako (Glostrup, Denmark), respectively. Leukemia-inhibitory factor (LIF) was kindly provided by Dr A. Godard (U211, Nantes, France).

HMCL and cell culture conditions. The HMCL LPl and NCi H929 were purchased from DSM (Braunschweig, Germany), and RPMI 8226 was from American Type Culture Collection (Rockville, MD). They were maintained in RPMI-1640 supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 µg/mL streptomycin, 100 U/mL penicillin, 5 x 10⁻⁵ mol/L 2-β mercaptoethanol, as previously described. Freshly-expanded, pure and slowly growing, 6-month-old myeloma cells from a malignant pleural effusion (SBNI) were maintained in similar conditions of culture. SBNI cell growth was totally dependent on conditioned medium (i.e., pleural effusion) or recombinant IL-6 (rIL-6). Freshly explanted myeloma cells (purity, >80%) were obtained from Oncogénie Immunohématologique Inserm U211, Institut de Biologie, Nantes; Leo Pharmaceuticals, Saint Quentin Yvelines; Dianclone Research, Besançon, France.

Submitted February 5, 1996; accepted August 2, 1996.

Supported by Leo Pharmaceuticals and the Ligue départementale de Latte contre le Cancer de Loire-Atlantique.

Address reprint requests to Régis Bataille, PhD, Laboratoire d'Oncogénie Immunohématologique Inserm U211, Institut de Biologie, 9, quai Moncousu 44035 Nantes cedex 01, France.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1996 by The American Society of Hematology.
after Ficoll-Hypaque separation from the peripheral blood of a patient with MM during a terminal leukemic phase.

Proliferation assays. Proliferation assays were performed in 96-well round-bottom microtiter plates at a cell density of 10^5 cells/mL. As previously described, 12 cell cultures were incubated for 3 days at 37°C in a 5% CO₂ humidified atmosphere. Then, 1 mCi of [²H]-thymidine was added during the last 18 hours. [²H]-thymidine incorporation was quantified by liquid scintillation spectroscopy.

BM stromal cell culture. BM mononuclear cells were isolated by Ficoll-Hypaque density sedimentation. The cells were cultured in RPMI-1640 supplemented with 10% fetal calf serum. After 2 or 3 weeks, a confluent adherent cell monolayer was obtained. Then, after 2 passages using trypsin/EDTA solution, they were used for assays.

Cytokine production, with 15 pg/mL of IL-6 and soluble IL-6Ra (Diaclone Research) was measured by enzyme-linked immunoadsorbent assay (ELISA) using a commercially available kit for IL-6 and soluble IL-6Ra (Diaclone Research).

Northern blotting. Total RNA was extracted from myeloma cells using the isothiocyanate phenol method. Total RNA (25 μg) was separated on a 1% agarose gel after denaturation with glycoxal and dimethyl sulphoxide. Blotting onto nylon membranes, hybridization, washing, and developing were performed using standard methods. Membranes were hybridized with the gp80 and gp130 cDNA probes. After developing, the membranes were stripped and rehybridized with a glyceraldehyde-3-phosphate dehydrogenase cDNA probe.

Flow cytometry analysis. For immunofluorescence staining of HMCL, 5 x 10⁴ cells were incubated with different MoAbs for 30 minutes at 4°C, then incubated with a goat antimouse fluorescein isothiocyanate conjugate (Immunotech, Marseilles, France). Cells were fixed in 4% formaldehyde and analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). To determine the level of positivity for each marker, we divided the mean fluorescence intensity of each marker by that of the control staining, thus, defining the intensity fluorescence ratio.

RESULTS

Inhibition of myeloma cell growth by 1,25(OH)₂D₃: Comparison with the new vitamin D₃ derivative EB1089.
INHIBITION OF MYELOMA CELL GROWTH BY A VITD~ DERIVATIVE

EB1089 is a new vitamin D derivative with potent inhibitory effects on leukemic cell growth in vitro. Thus, it was tested on the three HMCLs and the fresh IL-6–dependent myeloma cells SBN1 and compared with 1,25-(OH)2D3. As previously emphasized by ourselves on RPMI 8226 and as outlined in Fig 1, 1,25-(OH)2D3 inhibits not only the growth of the three HMCLs but also that of the IL-6–dependent SBN1 cells in a dose-dependent way. However, whereas a progressive inhibition is observed with RPMI 8226 with significant effects at doses as low as 10−12 mol/L, no effect is observed with LP1, NCI H929, and SBN1 cells until a dose of 10−10 mol/L is used, with significant effects beginning at 10−9 mol/L. Of note, EB1089 gives similar response curves but turns out to be more efficient than 1,25-(OH)2D3 on the three HMCLs and SBN1 cells at least at 10−8 and 10−9 mol/L (Fig 1). This is especially true for LP1 and SBN1 cells (54% and 51% inhibition, respectively, with EB1089 vs 7% and 3%, respectively, with vitamin D3 at 10−9 mol/L). Of major interest and as previously emphasized, the inhibition of SBN1 is observed in the presence of rIL-6 because the growth of these cells (as opposed to that of the other HMCLs) is totally dependent on IL-6. The concentration of 10−8 mol/L was chosen for the next experiments performed with EB1089 because a maximum of inhibitory effects is observed at this concentration (71% of inhibition for LP1, 58% for NCI H929, 42% for RPMI 8226, and 73% for SBN1 cells).

Inhibition of myeloma cell growth by EB1089: Comparison with Dex. As previously emphasized and as recently reassessed by ourselves,12 Dex is a potent inhibitor of myeloma cell growth in vitro. In our experience, a ≥20% inhibition of growth is observed in six of six HMCLs independent of exogenous IL-6 to grow (the current study and Juge-Morineau et al15). For treatment in vivo, Dex is used at a concentration of 10−7 mol/L; this concentration also has been chosen for the following experiments. As shown in Fig 2, Dex significantly inhibits the growth of LP1 and NCI H929 (99% and 58% inhibition, respectively) but has a less significant effect on RPMI 8226. Of note, the effect of the combination of EB1089 and Dex is always superior to the effect of each one alone, and, only on RPMI 8226, does EB1089 have additive effects to those of Dex. With respect to the SBN1 cells, which are totally dependent on IL-6 to grow, it is impossible to inhibit their growth with Dex in the presence of IL-6. On the other hand, and as indicated in the previous section (Fig 1), a significant inhibition of these cells is observed with EB1089, despite the presence of IL-6. Finally, the combination of EB1089 and Dex has no greater effect than that of EB1089 alone (data not shown).

Table 1. Effects of Dex and EB1089 on the Cell Cycle Distribution of LP1 Cells

<table>
<thead>
<tr>
<th>Drug Exposure</th>
<th>G1</th>
<th>S</th>
<th>G2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>43.3 ± 2.2</td>
<td>40.6 ± 3.5</td>
<td>15.3 ± 2.3</td>
</tr>
<tr>
<td>Dex</td>
<td>90.2 ± 1.0</td>
<td>6.0 ± 1.3</td>
<td>3.7 ± 0.8</td>
</tr>
<tr>
<td>EB1089</td>
<td>73.91 ± 5.7</td>
<td>15.3 ± 4.2</td>
<td>11.47 ± 2.0</td>
</tr>
<tr>
<td>Dex + EB1089</td>
<td>94.0 ± 2.1</td>
<td>3.5 ± 1.3</td>
<td>2.7 ± 0.7</td>
</tr>
</tbody>
</table>

Data are expressed as the mean ± SD of five experiments.

* Two-day drug exposure. Dex and EB1089 were used at 10−7 mol/L and 10−9 mol/L, respectively.
† The percentage of cells in different phases of the cycle (among nonapoptotic cell population) after treatment with the different drugs is presented.
EB1089 induces G1 growth arrest by itself but induces apoptosis in synergy with Dex. When the cell cycle was analyzed, EB1089 turned out to have potent cytostatic effects without inducing apoptosis in our experimental conditions at 3 days. Indeed, in five experiments, a significant reduction of the percentages of myeloma cells in S phase was observed (40.6% ± 3.5% v 15.3% ± 4.2%; P = .01), with a significant increase of the percentages of myeloma cells in the G1 phase (43.3% ± 2.2% v 73.9% ± 5.7%; P = .01; see Table 1). Of note, these effects are similar to although less marked than those of Dex as shown in the Table 1.

Flow cytometry analysis of the DNA content indicates that EB1089 or Dex used alone cannot trigger apoptosis of myeloma cells in our current experimental conditions within 3 days. On the contrary, treatment of LP1 cells with a combination of the two drugs leads to a strong induction of apoptosis that is shown after 2 days by the appearance of a hypodiploid DNA peak that identified the apoptotic cell population (29%), as shown in the typical experiment represented in Fig 3.

IL-6, LIF, OSM, and an agonistic anti-gp130 MoAb cannot prevent the apoptotic effects of EB1089 with Dex. We12 and others3 have recently shown that IL-6, even at low doses (10 pg/mL), and some other cytokines belonging to the gp130 family such as LIF and OSM could be the major factors responsible for the resistance of myeloma cells to Dex. Because EB1089 has cytostatic effects on myeloma cells too, we have examined the capacity of IL-6, LIF, and OSM to reverse these effects in comparison with those of Dex. As shown in Fig 4A, on LP1 cells, IL-6 only partially reverses the inhibitory effects of EB1089, whereas it reverses totally those of Dex. On the other hand, LIF and OSM totally reverse the inhibitory effects of both EB1089 and Dex. However, because EB1089 and Dex have potent synergistic effects to induce apoptosis of myeloma cells, we have examined the capacity of IL-6, LIF, and OSM to prevent these effects. As shown in Fig 4A, IL-6, LIF, and OSM have only minimal effects to prevent those of EB1089 in combination with Dex. Of note, IL-6 at doses as high as 20 ng/mL (which are generally encountered in the myeloma intermediate milieu) are unable to prevent the effects of both EB1089 and Dex (data not shown). BS12 has been described as an agonistic anti-gp130 MoAb with IL-6-like effects on HMCLs.16 In the current study, such agonistic effects have been reproduced on LP1 (Fig 4B), with the BS12 MoAb being able to reverse the inhibitory effect of Dex better than IL-6. Of major interest, BS12 is unable to prevent the effects induced by the combination of EB1089 and Dex, although it partially reverses those of EB1089 alone (Fig 4B).

EB1089 downregulates the expression of the gp80 on myeloma cells and reduces the production of soluble IL-6RA. Considering that IL-6 and BS12 only partially reverse the inhibitory effects of EB1089, we have investigated the effect of EB1089 on the expression of both gp80 and gp130 in
INHIBITION OF MYELOMA CELL GROWTH BY A VITD3 DERIVATIVE

A

IL-6  
OSM  
LIF

Dex  
Dex+IL-6  
Dex+OSM  
Dex+LIF

EB  
EB+IL-6  
EB+OSM  
EB+LIF

Dex+EB  
Dex+EB+IL-6  
Dex+EB+OSM  
Dex+EB+LIF

[3]H TdR uptake (% of control)

LP1

B

BS12  
DEX  
DEX + BS12  
EB  
EB + BS12  
DEX+EB

Dex + EB + BS12

[3]H TdR uptake (% of control)

LP1

Fig 4. (A) Effect of IL-6, LIF, and OSM on the inhibitory effects induced by Dex, EB1089, and Dex plus EB1089. Cells (10^6/well) were cultured for 72 hours in the different conditions as indicated. Dex and EB1089 were used at the concentration of 10^{-7} and 10^{-8} mol/L, respectively. IL-6 was added at 125 pg/mL and LIF and OSM were added at 10 ng/mL. (B) Effects of BS12, an agonist anti-gpl30 MoAb, on the inhibitory effects induced by Dex, EB1089, and Dex plus EB1089. Dex and EB1089 were used at the concentrations of 10^{-7} and 10^{-8} mol/L, respectively. BS12 was added at 0.1 µg/mL.

The generation of new vitamin D3 derivatives such as EB1089 with potent antileukemic effects in vitro at least prompted us to investigate them on human myeloma cells, considering the presence of specific receptors for vitamin D3 on such tumor cells. In the current study, we have shown that 1,25(OH)2D3 and EB1089, a new vitamin D3 derivative, inhibit the growth of all myeloma cells tested, even those growing in the presence of IL-6, a major survival and growth factor for myeloma cells. EB1089 is clearly more potent than 1,25(OH)2D3 and is significantly efficient at 10^{-9} and 10^{-8} mol/L on the three HMCLs (even at 10^{-12} mol/L on RPMI 8226) and on fresh proliferative myeloma cells. The efficacy of EB1089 was compared with that of Dex, first, because Dex is well known to exert an inhibitory effect on the proliferation of myeloma cells in vitro and, second, because Dex is a steroid of reference in the treatment of MM. In the current study, on three HMCLs independent of exogenous IL-6 administration, EB1089 was clearly less efficient than Dex on LP1, the HMCL most sensitive to Dex, but was as efficient on NCI H929 and was more efficient on RPMI 8226. On the other hand, Dex lacked any inhibitory effect on SBN1 cells, which are myeloma cells totally dependent on IL-6 for growth, whereas EB1089 had significant inhibitory effects. The lack of correlation between the effects of EB1089 and those of Dex suggests that both drugs have different mechanisms of action. This is highly likely because it has been shown on a human breast cancer cell line that the antiproliferative effects of EB1089 might be related to promoter selectivity and were not mediated by inhibition of
Fig 5. (A) Regulation of gp80 on LP1 after treatment with EB1089 or Dex or EB1089 plus Dex for 24 hours: ( ), staining with an isotype control antibody; ( ), staining with MT18 MoAb without treatment; and ( ), staining with MT18 MoAb after the indicated treatment. (B) Regulation of gp130 on LP1 after treatment with EB1089 or Dex or EB1089 plus Dex for 24 hours: ( ), staining with an isotype control antibody; ( ), staining with AM64 MoAb without treatment; and ( ), staining with AM64 MoAb after the indicated treatment.

Table 2. Effects of Dex and EB1089 on the IL-6Ra (gp80) and β (gp130) Expression Analyzed by Flow Cytometry

<table>
<thead>
<tr>
<th>24-h Drug Exposure</th>
<th>gp80</th>
<th>gp130</th>
<th>gp80</th>
<th>gp130</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>2.15 ± 0.15</td>
<td>2.58 ± 0.26</td>
<td>2.49 ± 0.02</td>
<td>1.48 ± 0.07</td>
</tr>
<tr>
<td>Dex</td>
<td>3.75 ± 0.27</td>
<td>6.96 ± 0.29</td>
<td>4.25 ± 0.04</td>
<td>2.1 ± 0.12</td>
</tr>
<tr>
<td>EB1089</td>
<td>1.38 ± 0.01</td>
<td>2.39 ± 0.19</td>
<td>1.96 ± 0.04</td>
<td>1.21 ± 0.12</td>
</tr>
<tr>
<td>Dex + EB1089</td>
<td>1.55 ± 0.24</td>
<td>5.37 ± 0.14</td>
<td>3.47 ± 0.13</td>
<td>1.77 ± 0.15</td>
</tr>
</tbody>
</table>

Values shown are the mean fluorescence ratio ± SD.
niscient of those showing the downregulation of epidermal growth factor receptor levels by 1,25(OH)2D3 in human breast cancer cells.22 The regulation of some critical growth and differentiation factor receptors could be a key physiological role of this hormone. In parallel, we also found that Dex could strongly upregulate both gp80 (and the production of soluble IL-6Ra) and gp130 expression, as previously observed on epithelial cells,24 hepatocytes,25 and osteoblasts26 and as recently shown on myeloma cells by Chen et al.27 However, we found that EB1089 could inhibit the upregulation of gp80 expression by Dex while significantly limiting that of gp130. Whereas Dex significantly inhibited the IL-6 production by stromal cells, EB1089 had a weak but significant stimulatory effect. However this effect is always annihilated in the presence of Dex. The fact that EB1089 could activate the IL-6 gene in stromal cells contrary to Dex is reminiscent of the IL-6 gene induction by 1,25(OH)2D3 in M1 cells.27 However, no activation was observed in the HMCLs. Whereas neither EB1089 or Dex alone was able to induce apoptosis, we discovered that EB1089 could induce apoptosis in about one third of myeloma cells in synergy with Dex. A striking observation is that IL-6 (at doses as high as 20 ng/mL), LIF, OSM, and even an agonistic anti-gp130 MoAb were unable to prevent it.

From a therapeutic point of view, all these observations are of major importance. Higher doses of EB1089 than those we have used in vitro can be achieved in vivo without any hypercalcemic effects.29 Although an excessive osteoclastic resorption is generally observed in patients with MM, the efficacy of EB1089 at 10−9 mol/L or even at 10−12 mol/L suggests that this drug could be used in vivo, especially if agents able to limit calcium uptake (glucocorticoids) and bone resorption (bisphosphonates) are associated. Although Dex has a clear-cut antitumoral effect in MM, some patients do not respond to this treatment, and finally all become resistant. There is more and more evidence that Dex inhibits the IL-6 gene transcription, at least in stromal cells and myeloma cells, by interacting directly with the autocrine/paracrine IL-6 network in MM.19 As a consequence, we and others have shown that low doses of IL-6 could counteract the antiproliferative effects of Dex on myeloma cells in vitro.15 Thus, in vivo, the overproduction of IL-6 observed in the microenvironment of patients with MM (ie, several nanograms per milliliter) could be a major cause for the resistance of myeloma cells to the inhibitory effects of Dex. Furthermore, its newly described effects on the IL-6Ra expression (ie, upregulation) and production (ie, increase) of soluble IL-6Ra could lead to the selection of myeloma clones sensitive to low amounts of IL-6 to survive and to grow. In this context, the effects of EB1089, if observed in vivo could be of major therapeutic interest as a maintenance treatment. Because EB1089 (1) has potent cytostatic effects on human myeloma cells by itself even in presence of IL-6, (2) acts in synergy with Dex to induce unescapable apoptosis, and (3) inhibits both gp80 expression and production of the soluble IL-6Ra while counteracting the deleterious effects of Dex (ie, upregulation of both gp80 and gp130 expression), its association with Dex could be very helpful in the treatment of MM. Finally, it has been recently shown that the sensitivity of human myeloma cells to the cytotoxicity of immune cells inversely correlates with the degree of gp80 expression.30 In this context, EB1089 could facilitate the cytotoxicity of immune cells against myeloma cells.

Table 3. Effects of Dex and EB1089 on the Production of the Soluble IL-6Ra Determined by ELISA

<table>
<thead>
<tr>
<th>48-h Drug Exposure</th>
<th>Soluble IL-6Ra (ng/mL)</th>
<th>Exp 1</th>
<th>Exp 2</th>
<th>Exp 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.6</td>
<td>5.6</td>
<td>11.5</td>
<td></td>
</tr>
<tr>
<td>Dex</td>
<td>5.3</td>
<td>7.3</td>
<td>16.9</td>
<td></td>
</tr>
<tr>
<td>EB1089</td>
<td>1.5</td>
<td>1.6</td>
<td>8.2</td>
<td></td>
</tr>
<tr>
<td>Dex + EB1089</td>
<td>1.6</td>
<td>1.9</td>
<td>8.3</td>
<td></td>
</tr>
</tbody>
</table>

Fig 7. IL-6 production by stromal cells derived from two myeloma patients. Stromal cells were cultured for 48 hours with EB1089, Dex, or a combination of Dex plus EB1089; then, the supernatant was collected for IL-6 determination by ELISA.

ACKNOWLEDGMENT

We would like to thank Prof Kishimoto (Department of Medicine III, University Medical School, Osaka, Japan) and Dr Taga for providing us with the MT18 and AM64 MoAbs and L. Bataille-Zagury for editing the English text.

REFERENCES


Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone

D Puthier, R Bataille, S Barille, MP Mellerin, JL Harousseau, A Ponzio, N Robillard, J Wijdenes and M Amiot